文献速递心境障碍

裸盖菇素与氯胺酮共享机制:超越致幻效应的治疗潜力

The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine.
PubMed 文献 · Mol Psychiatry · 2025-07-07

本综述综合氯胺酮与裸盖菇素的临床和临床前研究,聚焦分子靶点、环路效应及下游通路汇聚。两者分别靶向NMDA受体和5-HT2A受体,均通过BDNF-TrkB信号促进突触生成,实现快速持久抗抑郁效应。5-HT2A受体偏向性激动可能分离裸盖菇素的治疗与致幻作用。

要点

  • 氯胺酮与裸盖菇素均通过BDNF-TrkB信号促进情绪调节环路的突触生成。
  • 5-HT2A受体偏向性激动是分离裸盖菇素治疗与致幻效应的潜在策略。
  • 理解血清素、谷氨酸与神经营养系统汇聚可指导非致幻快速抗抑郁药开发。

核心结论

  • 氯胺酮与裸盖菇素通过不同分子靶点汇聚于BDNF-TrkB信号,共同促进突触生成,为快速持久抗抑郁效应提供共享机制基础。
  • 5-HT2A受体偏向性激动有望在保留裸盖菇素治疗效应的同时剥离其致幻作用。

研究设计与样本

  • 本综述综合氯胺酮与裸盖菇素的近期临床与临床前研究,比较其分子靶点、环路效应及下游通路。

主要发现

  • 氯胺酮为NMDA受体拮抗剂,裸盖菇素为主要靶向5-HT2A受体的血清素能致幻剂,二者均在情绪调节环路中增强突触可塑性。
  • BDNF-TrkB信号是二者共享的关键机制,促进树突棘生成与突触形成,对维持抗抑郁疗效至关重要。

临床怎么用

  • 临床可关注BDNF-TrkB信号作为快速抗抑郁药共享靶点,并探索5-HT2A受体偏向性激动策略以开发非致幻类药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Major depressive disorder is a debilitating condition, with many patients unresponsive to conventional monoaminergic antidepressants. Rapid-acting antidepressants such as ketamine and psilocybin offer promising alternatives, relieving symptoms within hours. Ketamine, an NMDA receptor antagonist, and psilocybin, a serotonergic psychedelic primarily targeting 5-HT2A receptors, both enhance synaptic plasticity in mood-regulating circuits through distinct mechanisms. This review synthesizes recent clinical and preclinical findings on ketamine and psilocybin, emphasizing their molecular targets, circuit-level effects, and converging downstream pathways. A key shared mechanism involves BDNF-TrkB signaling, which promotes spinogenesis and synaptogenesis critical for sustained antidepressant efficacy. We also discuss 5-HT2A receptor biased agonism as a potential strategy to dissociate psilocybin's therapeutic effects from its hallucinogenic actions. By comparing their mechanistic profiles, we identify both overlapping and distinct features that may inform the development of next-generation rapid-acting antidepressants. Understanding how serotonergic, glutamatergic, and neurotrophic systems converge may guide the development of fast-acting, durable, and non-hallucinogenic antidepressants.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Park D, Lee G, Lee WG, et al. The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine. Mol Psychiatry. 2025. PMID: 40624295. doi:10.1038/s41380-025-03100-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。